Technology platform

A Unique Targeted Radionuclide Therapy (TRT) Radiometal Platform
Patient case (#2)
NCT02683083

A Unique Targeted Radionuclide Therapy (TRT) Radiometal Platform

Precirix platform allows the design and development of novel radiopharmaceuticals or targeted radionuclide therapies, a technology in which radionuclides are attached to ligands that direct them to their specific target on the cancer cell with exceptionally long tumor retention times. The radioactive payload is delivered, in a highly selective manner to the tumor, limiting radiation to the rest of the body.

Our technology platform facilitates development of single domain antibodies (sdAbs) for multiple targets, in combination with different isotopes and applicability in various settings.

A Unique platform

Single-domain antibody targets the cancer

CAMs combine the benefit of conventional mono-clonal antibodies and peptides

Peptide like properties include small size, high solubility, fast tumor penetration and rapid blood clearance

Monoclonal antibody like properties include high target specificity, high affinity, exceptional stability and long tumor retention

Radioisotope kills through DNA breaks

Direct cell killing and bystander effects

A Flexible platform

Powerful Platform Technology

Target any extracellular tumor antigen

Short development timelines

Predictable process

Different isotopes

Suitable for any radiometal

Therapeutic and diagnostic use

Alpha and beta emitters


CAM-TRT attributes

High target specificity and affinity

Fast tissue penetration

Rapid blood clearance

Pipeline

CAM-FAP is our lead program. It is a single domain antibody construct that targets fibroblast activation protein alpha and is nearing IND readiness.

In addition to the lead program, the company has several molecules in the advanced pre-clinical stage including one targeting folate receptor alpha and several undisclosed targets.

  Hit Lead Ind enabling Phase Ⅰ Phase Ⅰ/Ⅱ
CAM-FAP-Ac-225 FAP+ solid tumors incl. pdac, gastric
CAM-FAP-ga-68 Imaging FAP+ solid tumors
CAM-FAP-Lu-177 FAP+ solid tumors incl. pdac, gastric
CAM-HER2-Ac-225 HER2+ breast, gastric, GEJ
CAM-HER2-Lu-177 HER2+ breast, gastric, GEJ
CAM-HER2-Pb-212 Undisclosed
Orchestra Life Sciences
CAM-FR Ovarian
Collaboration
CAM-TRT 1* Undisclosed
sdAb license
CAM-TRT 2 Undisclosed
CAM-TRT 3 Undisclosed
CAM-TRT 4 Undisclosed
Phase 2 Ready Radiohalogen Platform Available for Partnering or Out Licensing
CAM-HER2-I-131 HER2+ breast with brain metastases

Clinical trial

A Unique Targeted Radionuclide Therapy (TRT) Radiometal Platform
Keyaerts et al. UZ Brussel, VUB
NCT03331601

The company has completed a phase 1 study to evaluate CAM-H2 in the treatment of patients with advanced/ metastatic HER-2 positive breast and gastroesophageal cancer with our without brain metastases.

This asset is phase 2 ready and available for partnering or out licensing. If interested in finding out more, please contact info@precirix.com.

NCT04467515

Key publications

Relevant literature

Presentations

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.